BLCO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BL

Mkt Cap

$5.88B

Volume

346.21K

Next Earnings

October 28th

Loading chart

BL

BLCOBausch + Lomb Corporation

BLCO

Pay with—

Available Balance0.00

BL

Mkt Cap

$5.95B

Volume

346.21K

Next Earnings

October 28th

Chart Financials Earnings News About Insider Filings

Veterinary Ophthalmology Equipment Market by Product, Animal Type, Application, End User, Region Report Forecasts Market to Reach USD 0.83 Billion by 2031, Growing at a 7.7% CAGRThe global veterinary ophthalmology equipment market is expected to grow from USD 0.57 billion in 2026 to USD 0.83 billion by 2031, at a 7.7% CAGR. Growth is driven by rising pet ownership, increased prevalence of animal eye diseases, and adoption of advanced diagnostic and surgical technologies. Treatment applications and surgical equipment segments are leading growth, with Asia Pacific emerging as the fastest-growing region.GlobeNewswire Inc. · Sep 24, 2026

BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond LaserBausch + Lomb (BLCO) announced that its SeeLyra femtosecond laser received European CE Mark approval, expanding its surgical technology portfolio. The platform uses live swept-source OCT for real-time visualization and precise surgical control in cataract, LASIK, and corneal procedures. A limited European launch is planned with broader availability expected in 2027. The global ophthalmic femtosecond lasers market is projected to grow at 7.5% CAGR through 2033.Zacks Investment Research · Sep 14, 2026

Nicox Announces Extension of Cash RunwayNicox SA announced an extension of its cash runway to beyond Q1 2028 with €8.4 million in cash as of August 31, 2026. The company expects an FDA approval milestone for NCX 470 by April 30, 2027, which would fund operations into 2029, with subsequent royalties potentially extending visibility further. Management changes include Doug Hubatsch transitioning to Chief Scientific Advisor and Siobhan Garbutt assuming leadership of the development team.GlobeNewswire Inc. · Sep 2, 2026

Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 OthersThe global ophthalmology devices market is projected to grow from $56.61 billion in 2025 to $99.22 billion by 2030, with a CAGR of 11.9%. Key growth drivers include rising demand for minimally invasive surgeries, an aging population, increased eye disorders, and innovation in precision surgical tools. Leading companies include EssilorLuxottica, Alcon, Bausch + Lomb, and HOYA Corporation, with North America currently leading the market while Asia-Pacific shows rapid growth potential.GlobeNewswire Inc. · Jul 13, 2026

A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the StoryBausch + Lomb director Alfonso Eduardo purchased 4,300 shares for approximately $77,000 on March 2, 2026, at $17.90 per share. The company matched his purchase with 4,300 restricted stock units granted at no cost, vesting over three years. As a new director (joined January 1, 2026), Eduardo is working toward a mandatory $400,000 equity ownership requirement within five years, with this transaction bringing him to roughly $248,000 of that threshold.The Motley Fool · Mar 24, 2026

Bausch + Lomb Corporation Investigated by the Portnoy Law FirmThe Portnoy Law Firm has initiated a securities fraud investigation into Bausch + Lomb Corporation following significant stock price declines. The company's stock fell 9.8% on March 28, 2025, after disclosing increased reports of toxic anterior segment syndrome (TASS) related to enVista intraocular lenses, prompting a voluntary recall. A second decline of 15.7% occurred on April 30, 2025, following Q1 2025 results estimating $55 million in revenue and $65 million in adjusted EBITDA headwinds from the recall.GlobeNewswire Inc. · Mar 13, 2026

Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major PositionBausch + Lomb reported $5.1 billion in annual revenue with 6% year-over-year growth, driven by contact lenses, consumer eye health products, and new pharmaceutical launches like MIEBO. Caspian Capital increased its stake by 1.35 million shares to $34.14 million, making it the firm's top holding at 22.6% of AUM. Despite underperforming the S&P 500 over the past year, the stock has stabilized recently and analysts view the investor's conviction as a positive signal.The Motley Fool · Mar 12, 2026

Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036The global ophthalmic drugs market is projected to reach US$41.88 billion in 2026 and grow at 7.9% CAGR through 2036, driven by biologic innovation, anti-VEGF therapies, AI-enabled diagnostics, and long-acting drug delivery systems. Key developments include expanded digital distribution channels and sustained-release implants reducing treatment burden for retinal disorders.GlobeNewswire Inc. · Feb 25, 2026

Nicox présente des données de Phase 3 positives confirmant le profil thérapeutique de NCX 470 lors du congrès annuel 2026 de l’American Glaucoma Society (AGS)Nicox announced positive Phase 3 data for NCX 470, a nitric oxide-donating bimatoprost eye drop, presented at the American Glaucoma Society 2026 congress. The drug demonstrated intraocular pressure (IOP) reduction up to 10 mmHg, meeting efficacy requirements for U.S. and China regulatory approvals. NCX 470 showed superior IOP reduction compared to latanoprost at three of six measurement points and demonstrated a favorable safety profile with low treatment discontinuation rates.GlobeNewswire Inc. · Feb 24, 2026

Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS)Nicox announced that Phase 3 study results for NCX 470, a nitric oxide-donating bimatoprost eye drop for glaucoma treatment, will be presented at the American Glaucoma Society annual congress in February 2026, including two oral presentations. The company is preparing regulatory submissions for NCX 470 in the United States and China with licensed partners Kowa and Ocumension Therapeutics.GlobeNewswire Inc. · Feb 10, 2026

to start trading

BL

BLCOBausch + Lomb Corporation

BLCO

Pay with—

Available Balance0.00

Your PositionYou don't own any BLCO yet.

Related Tickers

Earnings